\
&
Contact us
\
&
Contact us
Published on | 5 years ago
ProgrammesYesterday the European Commission appointed five new members for the Scientific Council of the European Research Council (ERC). The Scientific Council is the governing body of the ERC, which is composed of 22 members, scientists and scholars from across Europe. The four-year mandate of the new members starts on 1 January 2021. Among those new members is Professor Dirk Inzé from Ghent University. In addition to the five new Scientific Council members, the Commission reappointed 16 current members for the same period. The search process for the next President of the Scientific Council is still ongoing. The current President ad interim, Jean-Pierre Bourguignon, will be in office until the next ERC President is selected and takes up duties.
ERCEA press release with member biographies
Related news article
European Commission launched search for ERC Scientific Council members
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Civil Security Digital, Industry & Space Agro-Food, Environment
The European Innovation Council has launched a call to recruit independent experts of diverse innovative defence and dual-use technologies (as eg. maritime, medical, drones, financial expertise, ..). It is important for the EIC to have a solid batch of experts with a balanced national diversity. Note that, as a requirement and due to security sens... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
